Therapeutic Phlebotomy: Indications, Contraindications, and Protocol
Therapeutic phlebotomy is the first-line treatment for iron overload disorders, particularly hereditary hemochromatosis and polycythemia vera, with a structured two-phase approach targeting specific ferritin and hematocrit goals.
Primary Indications
The main indications for therapeutic phlebotomy include 1:
- Hereditary hemochromatosis (HFE-related and other forms)
- Polycythemia vera
- Secondary erythrocytosis (COPD, post-renal transplant, congenital cyanotic heart disease)
- Iron overload from other causes
- Testosterone replacement therapy-related polycythemia
Contraindications and When to Pause Treatment
Absolute contraindications:
- Hemoglobin <11 g/dL - phlebotomy must be discontinued 1
- Severe anemia from other causes
- Hemodynamic instability or severe cardiac impairment 1
Relative contraindications requiring dose adjustment:
- Hemoglobin <12 g/dL - reduce frequency or volume 1
- Advanced liver disease with poor tolerance
- Pregnancy (though not absolutely contraindicated; can be performed with careful monitoring)
Protocol for Hemochromatosis
Induction Phase 1
Volume and frequency:
- Remove 400-500 mL weekly or every 2 weeks
- Continue until target ferritin of 50 μg/L is achieved
Monitoring schedule:
- Check hemoglobin before each phlebotomy session
- Measure ferritin every month (or after every 4th phlebotomy)
- Once ferritin drops below 200 μg/L, check ferritin every 1-2 treatment sessions
Hemoglobin-based adjustments:
- If Hb <12 g/dL: reduce frequency or volume
- If Hb <11 g/dL: pause treatment entirely and investigate for other causes of anemia
Maintenance Phase 1
Target and frequency:
- Target ferritin: 50-100 μg/L
- Frequency: typically 2-6 phlebotomies per year (highly variable between patients)
- Average ferritin rises approximately 100 μg/L per year without treatment
Monitoring schedule:
- Check hemoglobin before each session
- Monitor ferritin and transferrin saturation every 6 months
- Life-long follow-up required
Protocol for Polycythemia Vera
- Women: <42%
- Men: <45%
Procedure:
- Fixed volume of 350 mL every 3 days until target achieved 2
- Alternatively, weekly phlebotomies can be performed
- Continue maintenance phlebotomy to keep hematocrit below target
Alternative Treatment Options
Erythrocytapheresis 1
When to consider:
- Patients who cannot tolerate standard phlebotomy hemodynamically
- When faster iron depletion is desired
- Availability and local expertise permit
Advantages:
- Fewer hemodynamic changes
- Fewer procedures needed in induction phase
- Returns valuable blood components
Disadvantages:
- Mild citrate reactions are common
- More expensive than standard phlebotomy
- Same target ferritin goals (Induction: 50 μg/L, Maintenance: 50-100 μg/L)
Iron Chelation Therapy 1
Only use as second-line treatment when phlebotomy is not feasible after careful risk-benefit assessment by a specialist.
Options:
- Deferasirox (DFX): 10-15 mg/kg oral, most studied but off-label
- Deferoxamine (DFO): subcutaneous infusion, can combine with mini-phlebotomies
- Deferiprone (DFP): oral, very limited experience, risk of agranulocytosis
Contraindications for all chelators:
- Pregnancy
- Advanced liver disease (especially for DFX)
- Renal failure (requires dose adjustment)
Monitoring for DFX:
- Monthly liver and renal function
- Audiological and ophthalmological review before starting and annually
Critical Patient Counseling 1
Dietary modifications (do NOT substitute for phlebotomy):
- Avoid iron supplements and iron-fortified foods
- Avoid supplemental vitamin C (enhances iron absorption)
- Limit red meat consumption
- Restrict alcohol intake; complete abstinence if advanced liver disease
Safety considerations:
- Avoid raw/undercooked seafood
- Avoid contact of wounds with seawater (Vibrio vulnificus risk)
Adjunctive therapy:
- Proton pump inhibitors (if prescribed for other indications) can reduce phlebotomy frequency by decreasing iron absorption 1
Common Pitfalls to Avoid
Over-treatment: Ferritin <20 μg/L significantly increases dietary iron absorption and can cause symptomatic iron deficiency 1. Stop before reaching iron deficiency.
Inadequate monitoring: Unexpected changes in ferritin or transferrin saturation warrant investigation for alternative causes (bleeding, malignancy, inflammation) 1.
Sending patients to "just donate blood": This is inappropriate. Therapeutic phlebotomy requires a prescribed course with specific targets and monitoring 4.
Ignoring hemoglobin: Always check hemoglobin before each procedure to prevent anemia 1.
Relaxing targets too much in elderly: While some experts suggest more relaxed maintenance targets (ferritin <200 μg/L for women, <300 μg/L for men), these are based on expert opinion and may compromise outcomes 1.
Special Populations
Juvenile hemochromatosis 1:
- Phlebotomy is first-line when possible
- Severe cardiac iron overload may require combination chelation therapy (DFP + DFO)
- More aggressive approach needed in induction phase
Pregnancy 3:
- Phlebotomy can be performed if needed
- If high-risk and requiring cytoreduction, use interferon-alpha (not chelators)
Advanced disease with poor tolerance 1:
- Consider mini-phlebotomies plus subcutaneous deferoxamine
- Refer to specialized centers
Blood Donation Eligibility
Patients with uncomplicated hemochromatosis without significant organ damage can serve as regular blood donors during the maintenance phase, making their blood available for transfusion 1. This provides both therapeutic benefit and community value.